Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vistagen Therapeutics (VTGN) Current Deferred Revenue (2020 - 2025)

Vistagen Therapeutics' Current Deferred Revenue history spans 5 years, with the latest figure at $2.0 million for Q4 2025.

  • For Q4 2025, Current Deferred Revenue fell 20.36% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, down 20.36%, while the annual FY2025 figure was $2.6 million, 227.18% up from the prior year.
  • Current Deferred Revenue for Q4 2025 was $2.0 million at Vistagen Therapeutics, down from $2.1 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $3.6 million in Q2 2021 and bottomed at $714300.0 in Q2 2023.
  • The 4-year median for Current Deferred Revenue is $2.0 million (2025), against an average of $1.9 million.
  • The largest annual shift saw Current Deferred Revenue crashed 67.37% in 2021 before it skyrocketed 227.18% in 2025.
  • A 4-year view of Current Deferred Revenue shows it stood at $1.4 million in 2021, then grew by 24.12% to $1.8 million in 2023, then skyrocketed by 42.39% to $2.5 million in 2024, then dropped by 20.36% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Current Deferred Revenue are $2.0 million (Q4 2025), $2.1 million (Q3 2025), and $2.5 million (Q2 2025).